Dr. Adam Koppel rejoined Bain Capital in 2016 as managing director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003, where he was a leader within the health care sector until mid-2014. During mid-2014 to mid-2016, Dr. Koppel was at Biogen, where he served as executive vice president of corporate development and chief strategy officer. He sits on the board of directors of PTC Therapeutics (NASD: PTCT) and Trevena (NASD:TRVN).
Prior to joining Bain Capital in 2003, Dr. Koppel was an associate principal at McKinsey & Co in New Jersey, where he served a variety of health care companies. Dr. Koppel received a medical degree and a PhD in neuroscience from the University of Pennsylvania School of Medicine. He also received a master of business administration from The Wharton School at the University of Pennsylvania, where he was a palmer scholar. He graduated magna cum laude from Harvard University with a bachelor of arts and master of arts in history and science.